2024 has become a pivotal year in the history of liver diseases with the long-awaited first FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH) – the fatty liver disease that big pharma had targeted for decades. First described in 1980, MASH is the advanced stage of metabolic-dysfunction-associated steatotic liver disease (MASLD) where […]
With summer in full swing, it’s a good time to relax, sit back and listen to Optimum’s amazing podcasts. Available on all the major outlets, you can take it with you anywhere – the office, the train, or even the beach! In Episode #23, we caught up with Dr Ruth McKernan CBE, neuroscientist, businesswoman and […]
Novo Holdings, a leading international life science investor, on Thursday announced a £50m investment in Oxford Nanopore Technologies, the leading UK Listed company behind a new generation of molecular sensing technology based on nanopores. Oxford Nanopore is developing a transformational new generation of sensing technology that specialises in DNA/RNA sequencing. The £50m was invested by […]
Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]
On Tuesday, Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation a driver of neurodegenerative disease, announced it had secured a $100 million Series C Financing that was led by Novo Holdings. This financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment […]
